The New York University School of Medicine Hub is conducting a large multisite trial to compare the effectiveness of extended-release buprenorphine (Sublocade, XR-B) to extended-release naltrexone (XR-NTX). The trial will enroll individuals prior to release from jail and randomize to either medication option. The first dose of medication will be administered prior to release, with an additional 24 weeks of treatment received in the community. Participating jails are located in Connecticut, Delaware, New Hampshire, New Jersey and Oregon. The study will measure retention in treatment, and opioid and other substance use outcomes between the two medication conditions, as well as a sample of individuals who opt for other treatment options (“treatment as usual”).
MD, MSc, New York University School of Medicine
PhD, New York University School of Medicine
MD, Dartmouth College
MD, Friends Research Institute
MD, Yale School of Medicine
MD, Oregon Health & Science University
Health Agency Partner
- Kasey Harding, Community Health Center, Inc.
Justice Agency Partners
- Thomas Groblewski, DO, New Hampshire Department of Corrections